Evidence map›Paper›PMID 40996958›Full record

ArticlePLoS genetics2025

From paleness to albinism: Contribution of OCA2 exon 10 skipping to hypopigmentation.

Elina Mercier, David-Alexandre Trégouët, Sébastien Campagne, Vincent Michaud, David J Green, Shahram Mesdaghi, Orane Le Gallais, Orphée Jouannigot-Castano, Daniel J Rigden, Catherine Estay-Ahumada and 4 more

Abstract read
In one paragraph

Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Molecular genetics and metabolism reports · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elina MercierRare Diseases Genetics and Metabolism, INSERM U1211, University of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0009-0003-8663-2710
David-Alexandre TrégouëtBordeaux Population Health Research Center, UMR 1219, University of Bordeaux, Inserm, Bordeaux, France.ORCID https://orcid.org/0000-0001-9084-7800
Sébastien CampagneCNRS, INSERM, ARNA, UMR 5320, U1212, University of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0002-0094-4760
Vincent MichaudRare Diseases Genetics and Metabolism, INSERM U1211, University of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0002-5788-392X
David J GreenDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Shahram MesdaghiDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular & Integrative Biology, Liverpool, United Kingdom.ORCID https://orcid.org/0009-0009-8328-5972
Orane Le GallaisRare Diseases Genetics and Metabolism, INSERM U1211, University of Bordeaux, Bordeaux, France.
Orphée Jouannigot-CastanoRare Diseases Genetics and Metabolism, INSERM U1211, University of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0009-0003-4016-6312
Daniel J RigdenDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular & Integrative Biology, Liverpool, United Kingdom.
Catherine Estay-AhumadaInstitute for Cellular and Integrative Neuroscience, CNRS UPR 3212, Strasbourg, France.ORCID https://orcid.org/0000-0003-4123-8915
David HicksInstitute for Cellular and Integrative Neuroscience, CNRS UPR 3212, Strasbourg, France.
Panagiotis I SergouniotisDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Benoit ArveilerRare Diseases Genetics and Metabolism, INSERM U1211, University of Bordeaux, Bordeaux, France.
Sophie JaverzatRare Diseases Genetics and Metabolism, INSERM U1211, University of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0003-3497-0542

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic variants in the OCA2 gene result in oculocutaneous albinism. In humans and several other mammalian species, OCA2 is transcribed into two coding mRNAs, a major transcript that encodes the full-length protein and a minor transcript that skips in-frame exon 10 and has no identified function. By contrast, rodents and non-mammalian vertebrates only express the major transcript. Several rare variants of human OCA2 have been reported to be pathogenic due to increased exon 10 skipping. To understand the vulnerability of human OCA2 to exon 10 skipping and its impact on pigmentation, we first functionally tested a series of rare missense variants spread across exon 10. We found that each variant significantly influences the skipping ratio either positively or negatively. By combining human and murine sequences in functional assays, we found that the skipping ratio depends on particular exonic and intronic combinations. Next, we focused on the most frequent exonic single nucleotide variant of human OCA2, rs1800404-T (c.1065G > A/p.Ala355=), located in exon 10. We show that this variant significantly promotes exon 10 skipping on its own and exhibits an additive effect in cis to previously identified splicing variants likely contributing to their pathogenicity. Association studies reveal that rs1800404-T is tightly associated with lighter skin and hair pigmentation in a representative European population, as has been observed in other populations around the world. Our structural models of the skipped transcript-derived protein support causality by predicting that it could exert a dominant-negative effect, which is consistent with a dose-dependent hypopigmentation response in both pathological and physiological contexts. Overall, the modulation of OCA2 exon 10 skipping by both benign and pathogenic variants provides a basis for improving the genetic diagnosis of albinism, and paves the way for research into the molecular and evolutionary mechanisms behind human pigmentation diversity.

Indexed as

Albinism, OculocutaneousHypopigmentationMembrane Transport ProteinsAlternative SplicingAnimalsExonsHumansIntronsMiceMutation, MissensePolymorphism, Single NucleotideMembrane Transport ProteinsOCA2 protein, human

Identifiers

PMID40996958
PMCPMC12463227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.